Cold thyroid nodules (CTNs) are characterized by a reduced iodide uptake in comparison to normal thyroid tissue. The sodium iodide symporter (NIS) is the first step in thyroid hormone synthesis and mediates the active iodide transport in the thyroid cells suggesting that decreased iodide uptake could be a result of changes in NIS expression or molecular defects in the NIS gene. In contrast to previous studies, an intraindividual comparison of NIS mRNA expression in CTNs and their corresponding surrounding tissue was performed using direct detection of NIS mRNA. A significant reduction in NIS mRNA expression was detected in 86% of the 14 investigated CTNs. We hypothesized that human sodium iodide symporter (hNIS) transcriptional failure could be caused by primary molecular NIS gene defects and/or methylation of DNA in the NIS promoter. However, no mutation in the NIS cDNA nor in the NIS promoter region upstream up to 2443 bp from the ATG start codon was detected. Therefore, primary molecular NIS gene defects were excluded. However, in 50% of CTNs with reduced NIS mRNA expression, the promoter region was hypermethylated. NIS mRNA expression in these hypermethylated CTNs only reached a maximum of 30% of the corresponding surrounding tissue. Hence, methylation of CpG islands in the NIS promotor could be a regulatory mechanism of NIS transcription in CTNs. Immunoblot revealed absent hNIS protein expression in the total cell membrane fraction in 45% of investigated nodules. In the majority of the remaining CTNs NIS protein expression was decreased in the nodule tissue compared to the corresponding surrounding tissue. For investigating protein expression immunhistochemistry has two advantages. First, the whole nodule area can be investigated, and second, NIS expression can be detected in areas where an immunoblot of a cell membrane fraction is negative. Interestingly, immunhistochemistry revealed higher NIS expression in 50% of CTNs compared to their corresponding surrounding tissues and NIS staining was predominantly intracellular. These data demonstrate that NIS protein expression does not reflect NIS mRNA expression. Therefore, factors that affect targeting of NIS to the plasma membrane are likely to be affected.
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Introduction
C
OLD THYROID NODULES (CTNs) are a commonly diagnosed problem, especially in regions with iodine deficiency. The large majority of CTNs are benign, only approximately 5% of all nodules are malignant (1), however, thyroid carcinomas usually present as CTNs on a scintiscan. The molecular mechanisms that cause CTNs are largely unknown. CTNs are characterized by a diminished iodide uptake compared to normal thyroid tissue (2) . A potential candidate gene for alterations in iodide uptake is the sodium iodide symporter (NIS) (3) . NIS mediates the active iodide uptake into thyroid cells, which represents the first step in the thyroid hormone synthesis (4, 5) . Since the discovery and cloning of NIS (6,7) tremendous progress has been made in understanding the mechanism of iodide transport and its possible disturbances (3) (4) (5) 8) . In addition, the availability of monoclonal and polyclonal antibodies against this integral membrane protein has permitted the functional characterization of NIS expression in several benign and malignant thyroid tissues. CTNs with a scintigraphically documented decreased iodide uptake suggest changes in NIS expression or a molecular defect in the NIS gene itself.
Higher than normal levels of NIS mRNA expression were observed in Graves` disease thyroid tissue and in toxic adenomas (9, 10) , whereas except for one study (11) a decreased NIS mRNA expression or a loss of NIS transcripts was detected in thyroid carcinomas and benign cold thyroid nodules (12) (13) (14) . Methods to examine NIS mRNA expression as well as their results differ significantly. NIS mRNA in CTNs was undetectable by Northern analysis (10) . The NIS mRNA). transcript was also undetectable by nonquantitative reverse transcription-polymerase chain reaction (RT-PCR) in 1 of 11 cold benign follicular adenomas (12) . An improved NIS mRNA quantification in CTNs was possible by real-time PCR. However, this study revealed a broad interindividual variation of NIS transcripts between different cold thyroid nodules (e.g., large interindividual variations of NIS mRNA). A reduction of NIS transcripts in CTNs compared to five pooled samples of normal thyroid tissues was observed with large interindividual variations ranging from 2-fold to 700-fold reductions (13) . Unlike the previous studies, we investigated intraindividual differences of NIS mRNA expression by a direct comparison of CTNs with their corresponding surrounding tissue. Moreover, detection of NIS mRNA was performed by RNase protection assay, which is more sensitive than northern blot analysis and allows for direct quantification of NIS mRNA without the need for cDNA production.
In order to investigate the molecular mechanisms that may influence NIS mRNA expression in CTNs, the NIS cDNA and the promoter region upstream up to 2443 bp from the ATG start codon were sequenced to search for mutations in the NIS gene, which may be responsible for the loss of iodide uptake. Furthermore, recent data suggest that DNA methylation may also be involved in the loss of NIS expression (15) . Data on the distribution of CpG-islands in the human genome and the degree of methylation of these islands improve the knowledge about the processes of normal and pathologic gene expression (16, 17) . Alterations of the normal gene expression may occur if CpG-islands in promoter regions are hypermethylated. In several studies inactivation of tumor suppressor genes or DNA repair enzymes by hypermethylation of the promoter has been demonstrated (18, 19) . In papillary thyroid carcinomas with undetectable or low NIS mRNA expression the human sodium iodide symporter (hNIS) promoter was strongly methylated (15) . Therefore, another aim of the present study was to investigate the methylation status of the hNIS promoter region in CTNs.
In contrast to reduced mRNA expression in CTNs, recent investigation of NIS protein expression using Western blotting revealed only slight differences between CTNs and normal tissues. However, a direct comparison between NIS mRNA and protein expression in these nodules was not performed (20) . Surprisingly, immunohistochemical studies have shown NIS overexpression in some thyroid carcinomas (21) , whereas in most studies a decreased mRNA was found (7, 12, 13) .
We directly compared NIS mRNA expression in CTNs with the corresponding surrounding tissue in order to obtain a more precise result for NIS mRNA expression than it can be obtained with a normalized control group. In addition, the protein expression was investigated by immunohistochemical studies, which have the advantages that nodule and surrounding tissue can be investigated simultaneously on one slide and information on NIS subcellular localization can be obtained. In all CTNs, in which sufficient nodule and surrounding tissue was available after surgery, the protein expression studies were extended to include an immunoblot analysis to allow for an intraindividual comparison of NIS mRNA and protein expression.
Subjects and Methods
CTN tissue samples
Tissue specimens of 42 scintigraphically CTNs and their surrounding normal tissue were obtained from surgery. All samples were immediately frozen in liquid nitrogen and stored at 280°C. Prerequisites for inclusion in the study were: (1) the identification of a solitary nodule by ultrasound, (2) a decreased technetium uptake by the nodule, and (3) the macroscopic and microscopic identification of the cold nodules by a pathologist. Thyrotropin (TSH) receptor antibodies were undetectable in all patients. Nodule and normal surrounding tissue were histologically classified according to World Health Organization (WHO) criteria (22) . Clinical and histopathological data of all CTNs are summarized in Table 1 .
The study was approved by the ethical committee of the University of Leipzig and the subjects gave informed consent.
The yield of nodule tissue obtained from surgery was very small in most cases. Therefore, not all nodules were available for all molecular studies.
RNA and DNA extraction
The total RNA was extracted using InViSorb RNA kit II (InViTek GmbH, Berlin, Germany). RNA samples were stored in DEPC-treated water at 220°C. Genomic DNA extraction was carried out using the QIAamp tissue kit (QIA-GEN, Chatsworth, CA). Plasmid DNA preparation was performed using the QIAprep Plasmid Mini Kit (QIAGEN).
Clonality
The clonality of CTN tissue was evaluated using X-chromosome inactivation based on PCR amplification of the human androgen receptor locus as previously described (23) . Fluorescence-labeled PCR products were examined using an ABI 373A Genetic Analyzer and the GeneScan Software supplied by the manufacturer (Applied Biosystems, Foster City, CA).
Generation of RNA transcription templates for RNase protection assay
The total RNA isolated from normal thyroid tissue was used to generate single-stranded cDNA (first-strand cDNA synthesis kit from Amersham Pharmacia Biotec, Braunschweig, Germany), followed by amplification of a 568-bp NIS cDNA fragment using the following primers; sense: GTG ATG CTA AGT GGC TTC TGG (cDNA position 936-956) and antisense: AAT CAC GAG TTT CCT GGG TG (cDNA position 1502-1483). This PCR fragment with an overlapping A-tail was cloned into the pGEM ® -T vector (22) . Clonality of nodules was evaluated using X-chromosome inactivation based on polymerase chain reaction (PCR) amplification of the human androgen receptor locus (23) . Except for four patients, of whom two were treated with levothyroxine, all patients with scintigraphically cold thyroid nodules were euthyroid with TSH levels in the normal range (0.25-4.0 mU/mL).
a TSH outside of the normal range. b Patients treated with levothyroxine. CTN, cold thyroid nodule; n. i., not informative; n. s., not studied.
in vitro transcription, this plasmid was cut with NotI (MBI Fermentas). To obtain the 75-bp GAPDH probe a pGEM-GAPDH plasmid (pGEM-vector containing a 548-bp human GAPDH cDNA fragment) was transcribed in vitro after digestion with DdeI (New England Biolabs, Schwalbach/Taunus, Germany).
Ribonuclease-Protection-Assay
The ribonuclease-protection assay (RPA) was performed using the Riboquant™-Kit (Pharmingen, San Diego, CA). Transcription-templates NIS-pBSK and pGEMGAPDH were labeled with [a-
32 P]-UTP by in vitro transcription using T7-RNA-polymerase. The [a-32 P]-UTP-labeled probes were hybridized for 12-16 hours at 56°C in solution in excess to different target RNA samples extracted from CTN tissue and the appropriate surrounding tissue. The remaining free probe and single stranded RNA was digested with RNases (Riboquant™-Kit). The RNase-protected probes were purified by phenol/chloroform extraction and ethanol precipitation, then separated on a 6% polyacrylamide gel, and finally quantified by phosphoimaging on the Molecular Imager System GS-525 with the Multi Analyst Software (BIO-RAD, München, Germany) or autoradiography on Kodak Biomax Film (Deisenhofen, Germany). The ratio of NIS/GAPDH was subsequently calculated. The specificity of NIS probes was verified by hybridization with RNA extracted from Graves' disease and euthyroid goiter tissue as positive controls and with a yeast tRNA as a negative control. Two independent experiments were performed per sample.
Preparation of cDNA, RT-PCR, and direct sequencing of the NIS gene
To prepare cDNA from the total RNA of cold thyroid nodules and surrounding tissues, 2 mg of RNA were added to a reaction mixture containing 53 first-strand buffer, 10 mM dNTP, 10 mM oligo dT primer, and 100 U Moloney murine leukemia virus reverse transcriptase (M-MLV RT; GIBCO BRL, Eggenstein, Germany). The RT reaction was carried out at 42°C for 60 minutes, 75°C for 10 minutes, and was terminated at 4°C. The NIS coding sequence was amplified from cDNA position 304 to 2422 in five overlapping fragments, ranging from 375 to 626 nucleotides. Oligonucleotide primers for amplification and sequencing of NIS cDNA and their appropriate annealing temperatures are listed in Table  2 . The PCR reactions were performed in a MJ Research thermocycler PTC 200 (Biozym, Oldendorf, Germany). Amplification of NIS cDNA fragments was performed in a 50-mL reaction mixture containing 0.5 mg of cDNA as template, 10 mM of each primer, 10 mM of each dNTP, 1 unit of Combi Pol polymerase (InViTek GmbH, Berlin, Germany), and the appropriate 103 incubation buffer with 1.5 mM MgCl 2 . The PCR conditions were as follows: 30 to 35 cycles consisting of denaturation for 30 seconds at 94°C, primer annealing for 1 minute at temperatures depending on the primer used (Table  2) , and extension for 1 minute at 72°C. For direct sequencing, PCR fragments were purified by polyethylene glycol (PEG) precipitation (13% PEG 8000, 10 mM MgCl 2 ) at room temperature. Purified PCR products were sequenced using BigDye terminator sequencing chemistry (Applied Biosystems). Sequencing reactions were analyzed on a Genetic Analyzer ABI 310 (Applied Biosystems). Furthermore, a part of the NIS promotor region upstream up to 2443 bp before the ATG start codon was amplified and sequenced using genomic DNA from nodular and surrounding tissue of 13 monoclonal CTNs. The primer sequences are listed in Table  2 . The PCR reaction and sequencing of purified PCR products were performed as described above.
Methylation-specific PCR analysis
This method uses PCR primer pairs to distinguish methylated from unmethylated DNA in bisulfite-modified target 
GGT GCA GAT AAT TCC GGT asNIS 2 CGG GAC TTT GCA GTA CAT TG 58ºC asNIS 2 CAC AAA CAT GAC GAT GCC AC asNIS 3
GCT GGC CCT GCT CAT CAA 56ºC asNIS 3 GCA GGC CGG CAG GAA CAT TC asNIS 4 TCT CAC TCA TCT ACG GAT CGG 60ºC asNIS 4 TGG CGT CCA TTC CTG AGC TG asNIS 5 GTG GCT CTC TCA GTC AAC GCC TCT 60ºC asNIS 5 TAG GGT AGG GTA TTG TAG TCC T asNISPro CTA GGT CTG GAG GCG GAG GTC G 64ºC asNISPro GTA GTC CCA GGC TCC GAA GGT G
The NIS coding sequence was amplified from cDNA position 304 to 2422 in five overlapping fragments as described in Subjects and Methods. The same primers were used for sequencing. The NIS promotor region upstream up to 2443 bp before the ATG start codon and up to 51 bp after the start codon was amplified and sequenced with the primer pair NISPro. Primer NIS 3 and NIS 5 were published elsewhere (9,36).
s, sense primer; as, antisense primer; NIS, sodium iodide symporter.
DNA, in which bisulfite converts unmethylated cytosines to uracil, but 5-methylcytosines remain as cytosines (24) . Two PCR reactions were performed for each DNA sample that detect originally methylated and unmethylated DNA, respectively. Modification of genomic DNA was performed as follows: 1 mg DNA was denatured by NaOH for 10 minutes at 37°C, then treated with 10 mM hydroquinone and 5 M sodium bisulfite for 16 hours at 50°C. The modified DNA was purified using the Wizard DNAcleanup system (Promega, Germany) according to the manufacturer`s protocol followed by treatment with 0.3 N NaOH for 5 minutes at room temperature before ethanol precipitation. PCR with primers, which distinguish between methylated (M-primers) and unmethylated (NM-primers) DNA focusing on CpG-rich regions of the NIS promotor (start: 2443 bp relative to the ATG start codon), was performed as described by Venkataraman et al. (15) . Methylation-specific PCR products of the promoter region, which were eluated from a polyacrylamide gel and purified by ethanol precipitation were sequenced using BigDye terminator sequencing chemistry (Applied Biosystems). Sequencing reactions were analyzed on a Genetic Analyzer ABI 310 (Applied Biosystems).
Production of a polyclonal NIS antibody
Peptide synthesis and antibody production was performed commercially by PINEDA Antibody Service, Berlin, Germany. A peptide corresponding to the C-terminal portion of the hNIS, amino acids 625-643 (SWTPCVGHDG-GRDQQETNL) was generated by solid phase synthesis and subsequently purified. The peptide was coupled to the carrier molecule keyhole limpet hemocyanin (KLH). Three rabbits were preimmunized in intradermal manner and later immunized subcutaneously. For preimmunization on the first day, Freund's complete adjuvant, and for the first, second, and third boost Freund's incomplete adjuvant were used. Their sera were tested by Western blot analyses 60, 90, and 120 days after boosting.
Generation of a NIS-positive control for Western blot analyses
To test the specificity of polyclonal antibodies, we generated a positive control for Western blot analyses. A 501-bp hNIS cDNA-fragment (cDNA position 1831 to 2332) was amplified using the following primers: forward 59ACGTG-GATGCACCCGGCTCTCCTCCCTGC TAAC 39 and reverse 59 ATCGTCTAGAGGCCCATCCTGAGGTTCCATCC 39. In order to clone this fragment into the pcDNA 3.1 (1) Zeo vector (Invitrogen, Carlsbad, CA) primers containing a restriction site for XbaI and BamHI at the 59 site were used.
Transfection of COS-7 cells
COS-7 cells were grown in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Inc.) supplemented with 10% fetal bovine serum (FBS), 1% glutamine and 1% penicillin/ streptomycin. At 75% confluence cells were subcultured in 12-well plates at a density of approximately 1 3 10 5 cells per well. The cells were transfected using the FUGENE 6 transfection reagent (ROCHE, Basel, Switzerland) according to the manufacturer's instructions with the pcDNA 3.1 plasmid containing the 501-bp hNIS fragment and with the pcDNA 3.1 vector alone. Forty-eight hours after transfection COS-7 cell membrane protein fractions were prepared.
Preparation of membrane protein fractions
Tissue samples and COS-7 cells were crushed in liquid nitrogen and resuspended in membrane preparation buffer (40 mM Tris/HCl, 250 mM sucrose, 0.1 mM dithiothreitol [DTT] and 0.1 mM phenylmethylsulfonyl fluoride [PMSF] at pH 7.4). The homogenates were first centrifuged at 700g for 10 minutes at 4°C. The supernatant was further centrifuged at 60000g for 45 minutes at 4°C to obtain the total postnuclear membrane fraction, which was resuspended in membrane preparation buffer. Protein concentrations were determined by measuring the absorption at 280 nm.
Western blot analysis
The membrane fractions of all tissue samples were heated at 37°C for 30 minutes in sample buffer (25) and electrophoresed (60 mg of protein per lane) on 9% polyacrylamide gels containing 0.1% sodium dodecyl sulfate using a discontinous buffer system described by Davis (26) . Separated proteins were electroblotted onto nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) using a semidry blotting system (BioRad, Hercules, CA). The membranes were blocked with 5% nonfat dry milk in TBS/T (20 mM Tris/HCl, pH 7.6, 0.8% NaCl, 0.1% Tween 20) for 1 hour at room temperature and incubated overnight with the polyclonal NIS-antibody (dilution 1:3000) at 4°C in TBS/T containing 5% bovine serum albumin (BSA). After washing three times for 5 minutes with TBS/T, the membranes were incubated for 1 hour at room temperature with a peroxidase-conjugated anti-rabbit antibody (New England Biolabs, Beverly, MA) diluted 1:3000 in blocking solution. Membranes were washed four times in TBS/T, and subsequently membranes were incubated with the chemiluminescence reagent (SuperSignal West Pico, Pierce, Rockford, IL) for 5 minutes at room temperature. Immunoreactive proteins were detected with ChemiImager 4000 (Alpha Innotech Corporation, San Leandro, CA) and quantified using Alpha Ease 4.0 software from Alpha Innotech Corporation. The measurements were repeated in two or three independent experiments.
Immunohistochemical analysis
Immunohistochemistry was performed on paraffin-embedded tissue blocks of 35 cold thyroid nodules. Several slides of 4-mm sections were made from every block. One slide of each patient was stained with hematoxylin and eosin and reviewed by a pathologist for diagnosis and confirmation of the diagnosis benign thyroid nodule. 4 mm sections were deparaffinated. Subsequently, microwave pretreatment for 15 minutes at 750 W was performed in citrate/Tris buffer (pH 9.0). Endogenous peroxidase activity was quenched by incubation in 3% of hydrogen peroxide for 20 minutes followed by two washes in TBS (50 mM TRIS, 150 mM NaCl, pH 7.6). Endogenous biotin activity was blocked for 20 minutes with DAKO Biotin Blocking System (DAKO Diagnostika GmbH, Germany). The slides were incubated for 1 hour with the monoclonal anti-NIS antibody (BrA 10-11, dilution 1:1000), which was kindly provided by BRAHMS Diagnos-tica GmbH. The initial concentration of the antibody was 4 mg/mL. The slides were washed three times for 2 minutes in TBS. Afterwards the slides were incubated with a biotinylated second antibody and a peroxidase-labeled streptavidin. Staining was completed after a 5-minute incubation with diaminobenzidine substrate chromogen, which resulted in a brown-colored precipitate at the antigen site (DAKO LSAB2 System, peroxidase, DAKO Diagnostica GmbH). Finally, all slides were counterstained with hematoxylin and mounted. Three stained slides were evaluated per sample. Graves' disease tissue was used as a positive control. A papillary carcinoma without NIS immunoreactivity served as negative control.
Immunohistochemical evaluation
The slides were examined for specific immunostaining in the nodule and surrounding tissue and scored independently by two of the authors. Immunostained cells were scored as follows: no immunostaining, 0; degree I, less than 30% cells stained; degree II, 30%-70% cells stained; degree III, more than 70% of cells stained (Table 3) .
Results
Histopathologic characterization and clonality
The histopathologic characterization, clonality of nodule tissues, and patients' characteristics (nodule size, TSH level, and age) are summarized in Table 1 . For all 42 CTNs with reduced technetium uptake on scintiscan, a corresponding macroscopic lesion was identified during surgery. In 13 cases, follicular adenoma and in 29 cases, adenomatous nodule was classified according to WHO guidelines (22) . In all nodules, a strong histologic heterogeneity of nodule tissues was observed as seen in representative nodules in Figure 5 . With the exception of 4 patients (3 treated with levothyroxine), all patients were euthyroid with a TSH level in the normal range. A clonal origin of cold nodular tissue was determined in 13 of 20 informative cases.
Determination of NIS mRNA expression
NIS mRNA expression in 14 CTNs and their corresponding surrounding tissues was examined by RNase protection assay (RPA). A 130-bp NIS mRNA fragment hybridized with the 32 P-labeled NIS in vitro RNA transcript probe was detectable in all tissue samples. A 75-bp GAPDH cDNA probe was used to normalize NIS mRNA transcripts for mRNA quantity. The NIS/GAPDH mRNA ratio was calculated after determination of the band intensity by densitometry (Fig.  1) . Quantitative densitometry and normalization of NIS mRNA for GAPDH mRNA revealed a strongly reduced NIS expression in 86% of the cold thyroid nodules in comparison with the corresponding surrounding tissue (Fig. 3) . The level of NIS mRNA expression was decreased by more than 65% in 10 CTNs (72% of the screened nodules). In 6 of these 10 nodules the NIS mRNA expression was lower than 10% (3%-9%) of the surrounding tissue (set at 100%). Two of the 14 nodules showed a decrease of NIS mRNA expression of 42%, and 32%, respectively, while no significant differences could be detected in 2 nodules (Fig. 3) .
Low TSH levels were measured in 4 patients, of whom 3 patients were treated with levothyroxine (Table 1) . However, the NIS mRNA expression in the 2 investigated nodules out of these 4 CTNs was similar to the other CTNs from patients with normal thyroid function (Fig. 3) . To investigate, whether reduced NIS mRNA expression in CTNs resulted from genetic alterations, the entire coding region of the NIS gene was sequenced. To increase the likelihood of finding somatic mutations only the 13 cold thyroid nodules, previously defined as monoclonal (27) (Table 1) were sequenced. No NIS mutations were found in these monoclonal CTNs. Subsequently, the search for mutations was extended to the NIS promoter region 2443 bp upstream of the ATG start codon, because mutations in this region could also cause a reduced NIS transcription. Functional analyses have indicated that this promoter region contains the minimal hNIS promoter (28). This was confirmed by another study, which showed that the area between nucleotides 2443 to 2395 is essential to confer promoter activity to the NIS gene (29) . The tentative hNIS transcriptional start site is located at 2375 nt upstream of the ATG site (28) . However, sequencing of the NIS promoter only revealed a previously not described mutation (GGC R GGT) in 1 of 13 CTNs and the corresponding surrounding tissue 70 bp before the ATG start codon. This base pair substitution likely represents a polymorphism, because this DNA variant was also detected in 6 of 50 healthy individuals (mutation frequency . 1%) (30) .
Methylation status
Methylation-specific PCR is a specific and sensitive method to determine methylation patterns of CpG islands. The hNIS promoter region, 2443 bp upstream of the ATG start codon, was analyzed in 14 CTNs also investigated by RPA to investigate the hypothesis that DNA methylation in critical regulatory regions could correspond to changes in promotor activity resulting in reduced NIS mRNA expres- 
FIG. 1. Sodium iodide symporter (NIS) mRNA expression in cold thyroid nodules (CTNs) compared to their corresponding surrounding tissue (ST) analyzed by RNase protection assay (RPA). Upper panel: CTN tissues (N) were directly compared to the corresponding surrounding tissues (S)
. Fifteen micrograms of total RNA were hybridized with the 32 P-labeled 130-bp NIS and 75-bp GAPDH probes. After RNase digestion, the RNase protected probes were separated on a 6% polyacrylamide gel and quantified by phosphoimaging. The expected bands are indicated by black arrows. The two bands for NIS mRNA observed for all samples are specific for NIS mRNA and are most likely caused by degradation of NIS mRNA. Both NIS mRNA bands differ merely by a size of 5-7 bp. The separate determination of NIS/ GAPDH ratio for these two bands yielded identical values. Lower panel: NIS/GAPDH mRNA ratio was calculated after the determination of the band intensity using densitometry. The NIS/GAPDH ratio of the surrounding tissue was set at 100% and the results of the CTNs were expressed as percentage of the surrounding tissues NIS/GAPDH ratio. Results from a single experiment are presented.
FIG. 2. Methylation analysis of the human sodium iodide symporter (NIS) promoter. A:
Products of methylation specific polymerase chain reaction (PCR) analysis of sodium bisulfite-modified genomic DNA from nodules and surrounding tissues using a methylation specific primer pair M and a nonmethylated specific primer pair (NM) were electrophoresed on an agarose gel. Order of the samples is as follows: 1, 100-bp ladder; 2, negative control for M-primers 
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sion in these CTNs. Analysis of DNA methylation in the promotor region revealed hypermethylation in 6 out of 14 CTNs compared to their respective surrounding tissue ( Fig.  2A) . Sequencing of these 6 CTNs for which a PCR product could be amplified with the methylation specific (M) primer pair, revealed cytosines at the four potential CpG islands in the promoter region (Fig. 2B) . Sequencing of the PCR products amplified with the nonmethylated-specific (NM) primer pair of the promotor revealed complete conversion to uracil (i.e., thymine was detected) at all CpG sites in the surrounding tissues as would be expected after bisulfite modification (Fig. 2B ).
In the 6 of 14 CTNs with a hypermethylated promoter region, NIS mRNA expression only reached a maximum of 33% of mRNA expression in their corresponding surrounding tissues (Fig. 3, right side) . In the remaining 8 CTNs, there was no apparent association of methylation with the level of NIS mRNA expression (Fig. 3, left side) . In 3 of these 8 CTNs, NIS mRNA expression was reduced by more than 90%; furthermore, in 3 CTNs, NIS mRNA expression was reduced in the range of 70%-32% and in the other 2 CTNs, no significant difference of NIS mRNA expression was determined.
Western blot analysis
To test the specificity of the polyclonal anti-NIS antibody COS-7 cells were transfected with the pcDNA3.1 plasmid containing the 501-bp hNIS fragment and with the pcDNA3.1 vector alone. The hNIS proteins could be detected with our polyclonal anti-NIS antibody as a band with the predicted molecular weight of approximately 18 KD in COS-7 cells transfected with the pcDNA3.1 vector containing the 501-bp hNIS fragment. This band was not detected in untransfected COS-7 cells or COS-7 cells transfected with the control pcDNA3.1 vector (data not shown).
NIS protein expression in 22 CTNs and their concomitant surrounding tissues were examined by Western blot analyses (Fig. 4) . For 7 of these 22 CTNs, NIS mRNA expression was also investigated by RPA. For a further 7 nodules, which were investigated for NIS mRNA expression (in total 14 CTNs were investigated by RPA), there was insufficient tissue available for Western blot analysis. Thus, a comparison of NIS mRNA and NIS protein expression determined by immunoblot was only possible for 7 nodules. Tissue samples showed a major band of approximately 80-90 KD, which was specific for hNIS (Fig. 4A) . Several minor bands with molecular weights of approximately 60-70 KD and approximately 50 KD were also visualized in some blots. The approximately 60-70 KD bands are nonspecific, because these bands could also be visualized after competition with the peptide for the C-terminal NIS antibody. hNIS protein was undetectable in 10 of 22 CTNs. Even at higher protein concentrations (up to 150 mg per lane), hNIS negative samples remained negative. NIS was detectable at protein concentrations of 40-60 mg per lane in the remaining 12 CTNs. Protein expression in nodule tissue was expressed as a percentage of surrounding tissue, which was set at 100%. NIS protein expression was significantly increased in 2 CTNs (133.3 6 5.4% and 209.2 6 37.2%) and decreased in 10 of these 12 CTNs within the range of 16%-74%. In 7 of these 12 CTNs, NIS protein expression was decreased by more than 50% compared to the corresponding surrounding tissue (Fig. 4B) . Comparison of results in a small group of 7 CTNs, which were investigated in parallel for mRNA (RPA) and protein expression by immunoblot showed that NIS protein expression did not correlate with NIS mRNA expression (data not shown).
Immunohistochemical analysis
In contrast to fresh tissue samples, of which the main part was retained for diagnostic issues, paraffin-embedded tissue was amply available from almost all CTNs. Therefore, NIS FIG. 3 . Sodium iodide symporter (NIS) mRNA expression in cold thyroid nodules and correlation with the methylation status of the NIS promoter region. NIS mRNA expression in nodule and surrounding tissue was determined by RNase protection assay as described in Subjects and Methods. mRNA expression in nodule tissue is expressed in percentage of the corresponding surrounding tissue (set at 100%). Moreover analysis of DNA methylation in the NIS promotor region was performed in these nodules. In hypermethylated nodules a methylation-specific polymerase chain reaction (M-PCR) product was detectable, in other nodules no M-PCR product was detectable. The promotor region of 6 of 14 CTNs was hypermethylated. In these 6 CTNs, NIS mRNA expression reached only a maximum of 33% of mRNA expression compared to their corresponding surrounding tissues (right). In the remaining 8 CTNs, there was no apparent association of methylation with the level of NIS mRNA expression (left).
tion (data not shown). Because this monoclonal antibody was not suitable for immunoblot analysis, a comparison between immunoblot and immunohistochemistry with the same antibody was not possible.
NIS immunostaining was found to be heterogenous in normal thyroid tissues as well as in CTNs. In addition, in CTNs the percentage of stained cells was highly variable and often staining was very diffuse. NIS was identified predominantly intracellularly in the majority of CTNs (Fig. 5A and  5C ). In contrast, in three toxic thyroid nodules, which were examined in parallel, a predominant membrane immunoreactivity for hNIS protein was observed. However, also intracellular staining was present (Fig. 5D) .
In 19 of the 35 CTNs, 30%-70% of follicular cells were positive for NIS (Table 3 ). However, as described above, NIS immunostaining was heterogenous and occurred in restricted areas. For quantitative analysis of NIS expression for each nodule and surrounding tissue, the size of the areas with prominent NIS staining was quantified. In only 4 of the 35 CTNs, more than 70% of follicular cells were NIS-positive and in 10 of the 35 CTNs less than 30% stained cells were identified. Two CTNs were negative for NIS immunostaining (Table 3 ). In 11 CTNs there was no or not enough surrounding tissue on the paraffin-embedded tissue block available to allow a direct comparison between NIS expression in the nodule and the surrounding tissue. Surprisingly, comparison between nodule and corresponding surrounding tissue in the remaining 24 CTNs revealed that NIS protein expression was higher in nodule tissue compared to surrounding tissue in 12 of the 24 CTNs (Table 3) as shown for CTN 65 and surrounding tissue 65 (Fig. 5A and 5B). In 9 of the 24 CTNs, NIS protein expression in nodule and surrounding tissues was comparable and only for 3 of the 24 CTNs, NIS protein expression in the nodule tissues was lower than in the surrounding tissues. There was no difference between follicular adenomas and adenomatous nodules. In 17 of the 35 CTNs, a comparison between immunoblot and immunohistochemistry results was possible. However, this comparison has to be considered carefully, because we used different antibodies for both approaches. Immunohistochemical analysis clearly revealed NIS expression in nodules, which did not show NIS bands in immunoblot analysis.
Discussion
CTNs were selected by detailed histopathologic and clinical characterization (Table 1) . Our study clearly demonstrates that a direct detection and quantification of NIS mRNA expression in benign CTNs is possible using RNase protection assay. Direct detection of NIS mRNA in benign CTNs as well as in nodules from euthyroid multinodular goiters was not possible in previous studies by the less sensitive Northern analysis (9, 10) . Moreover, intraindividual comparisons between CTNs and their concomitant surrounding tissues were performed to avoid bias by the large interindividual fluctuations described in previous studies (10, 13) .
We detected a significantly reduced NIS expression ranging from 3%-68% compared to the corresponding surrounding tissues in 86% of the cold thyroid nodules. This decreased NIS expression in CTNs is in line with the results of previous quantitative RT-PCR studies (10, 13) . However, in 20 CTNs, which were compared to 5 pooled normal tissues, a wide range of reduced NIS expression, ranging from 2-fold to 700-fold lower than in normal thyroid tissue, was detected by real-time RT-PCR (13). Our intraindividual comparison of NIS mRNA expression in CTNs tissues with their corresponding surrounding tissues revealed a much lower variation. In the 12 CTNs with a significantly decreased NIS mRNA expression, a 1.5-fold to 34-fold lower NIS expression than the surrounding tissue was determined. However, in 92% of these 12 nodules, the fold-decrease in NIS expression encompassed a much narrower range of 1.5-fold to 14-fold (Fig. 3) . Hence, our study demonstrates that the exclusion of interindividual influences permits a more reliable assessment of the relative NIS mRNA expression.
The clonality of cold nodules and their surrounding tissues was characterized to identify clonal cold nodules with increased probability for mutations, because advantageous somatic mutations could induce growth stimulation and induce clonal expansion (31) . To investigate whether a reduced NIS mRNA expression in clonal CTNs is caused by a primary somatic defect in the NIS gene, we sequenced the entire NIS cDNA from 13 monoclonal CTNs. Since the cloning of the human NIS, several germline mutations in this gene have been detected in patients with congenital hypothyroidism and iodide transport defects (32) (33) (34) (35) (36) (37) . Moreover, a mutation in the NIS gene has been identified in a patient with a huge euthyroid goiter (38) . However, no somatic mutation in the entire NIS cDNA was detected in our study of monoclonal CTNs with reduced NIS mRNA expression. Moreover, in the investigated NIS promotor region (2443 bp before the ATG start codon), except for one polymorphism, no alterations were found in the 13 investigated CTNs. Although we did not sequence the entire NIS promoter, but only a minimal promoter region (28, 29) , primary molecular defects in the NIS gene seem to be unlikely as a major cause for the loss of iodide uptake in cold thyroid nodules. These findings are compatible with a previous study reporting the absence of NIS gene mutations in differentiated human thyroid carcinomas, papillary and follicular carcinomas (39) . Krohn et al. (27) have demonstrated that ras mutations are rare in solitary CTNs. In only one patient with a CTN was a N-ras mutation detected. This study also showed the absence of mutations in exon 9 and 10 of the TSH receptor in CTNs (27) . Together, these results indicate that if CTNs are caused by somatic mutations, these mutations are most likely located in other perhaps yet unknown genes.
Alternatively, other factors such as alterations in the regulation of NIS transcript expression, alterations in protein synthesis or iodide organification could be involved (3). Inactivation of genes by hypermethylation of promoters can affect gene expression as drastically as mutations in the coding sequence itself (19, 40) . In human thyroid carcinoma cell lines, which lack hNIS mRNA, the demethylation of NIS DNA in the untranslated region within the first exon was shown to lead to a restoration of NIS transcription (15) . These findings suggest a role for DNA methylation in the loss of hNIS mRNA expression in thyroid carcinomas. Moreover, they suggest a therapeutic potential that might be derived from further understanding of promoter-(de)methylation processes. In the entire group of 14 CTNs that were investigated by RPA, there was no significant correlation between NIS mRNA expression and the degree of methylation (Fig.  3) . However, in 50% of cold thyroid nodules with reduced NIS mRNA expression the NIS promoter region was hypermethylated. NIS mRNA expression in these hypermethylated CTNs only reached a maximum of 30% of the corresponding surrounding tissue (Fig. 3) . Moreover, in CTNs with a hypermethylated NIS promoter, there was a tendency for lower NIS mRNA expression compared to CTNs with a nonmethylated promoter (Fig. 3) . Interestingly, Venkataraman et al. (15) , who investigated DNA methylation in dedifferentiated thyroid tumors, also failed to define specific methylation patterns associated with transcriptional failure. Because the NIS protein is heterogeneously expressed in normal thyroid tissues (41, 42) , it is conceivable that DNA methylation patterns of thyroid cells are distributed in the same manner. Moreover, as previously observed by Venkataraman et al. (15) we obtained amplification with the methylated primer set as well as with the unmethylated primer set in the nodules. This suggests heterogeneous methylation in CTNs. The absence of a specific methylation pattern also indicates the importance of other epigenetic factors, which may influence NIS mRNA expression in CTNs.
It is unknown whether the reduced NIS mRNA expression correlates with NIS protein expression. Recently, in 13 CTNs investigated by Western blot analysis a similar NIS protein expression was detected in cold nodules and the nonnodular tissue (20) . However, in contrast to the study of Russo et al. (20) , hNIS protein was undetectable in membrane fractions by immunoblot in almost 45% of our investigated CTNs. A similar observation was also reported in the study of Ruby et al. (43) , in which hNIS was undetectable in benign and malignant hypofunctioning tumors when assessed by immunoblot. In most of our nodules, NIS protein expression was decreased compared to the surrounding tissue. Because the immunoblot does not allow for determination of NIS localization within the different cellular com-partments, we also performed immunohistochemical analyses. Some previous immunohistochemical studies reported a low (less than 20%) or undetectable NIS immunoreactivity in the majority of thyroid follicles in CTNs (41, 44) . In contrast to these studies (41, 44) we found NIS staining of 30%-70% of the thyroid epithelial cells in two thirds of the CTNs. Moreover, a higher NIS protein expression was detected in half of all investigated nodules compared to the corresponding normal thyroid tissue when assessed by immunohistochemical analyses (Table 3) . However, NIS protein expression in CTNs was mostly localized intracellularly ( Fig. 5A and 5B). This result is in contrast to toxic thyroid adenomas, in which membrane immunoreactivity is predominant, but also intracellular NIS staining is visible (Fig. 5D) . Our findings are consistent with a recent study, which has shown overexpressed NIS protein in 54% of benign nonfunctional thyroid nodules compared to normal surrounding tissue. NIS was mostly located inside the cytoplasm in these nodules. However, hNIS protein was absent in 46% of the nonfunctioning nodules in this study (45) . In contrast in only 2 (5.7%) of our investigated nodules hNIS was not detected by immunohistochemistry. A predominant intracellular overexpression has also been reported in the majority (70%) of differentiated thyroid carcinomas (21, 46) . Obviously decrease in iodide uptake in most thyroid carcinomas is not caused by low NIS expression but most likely to alterations in NIS trafficking (47) . Indeed, our immunohistochemical findings underscore that in CTNs a large portion of the NIS protein remains trapped in the cytosol by mechanisms, which have to be investigated in further studies as NIS targeting to the plasma membrane and retention of NIS in the plasma membrane are essential for iodide transport into the thyroid follicular cells.
NIS protein expression is upregulated by TSH in vivo (48), however, little is known about the mechanisms by which TSH regulates NIS expression. Recently, it was demonstrated in FRTL-5 cells that TSH regulates NIS by posttranscriptional mechanisms (49) . In addition to the finding that TSH induces NIS de novo biosynthesis, the importance of TSH in the process of NIS targeting to or retention in the plasma membrane was demonstrated. TSH levels in almost all our patients with CTNs were in the normal range. Differences in NIS localization between CTNs and toxic thyroid nodules might indicate that the mechanisms of posttranscriptional regulation of NIS activity (5, 49) are likely to be different in cold and hot thyroid nodules. However, the finding that TSH-receptor mRNA expression in toxic thyroid nodules and cold nodules are in the normal range (13) could indicate that the cyclic adenosine monophosphate (cAMP)-mediated biosynthesis of NIS cannot be the only control mechanism.
Surprisingly, we observed NIS immunostaining in CTNs in which NIS protein could not be detected by immunoblotting. One reason for this finding might be that different NIS antibodies were used in each approach. More importantly, it should be noted that membrane fractions were investigated by immunoblot, whereas examination of paraffin slides showed a predominant intracellular localization for NIS immunoreactivity. Another explanation for these differences could be the advantage of immunohistochemistry allowing the analysis of the whole nodule area, whereas tissue samples used in Western blotting only represent an average value for part of the CTN, because the larger portion had to be used for histopathologic investigation. Moreover, the NIS distribution in thyroid tissues is heterogeneous. This could be one reason why less NIS protein was detected in some tissue areas used for immunoblot than we would have detected if we had used the whole nodule tissue. Therefore, immunohistochemical analysis seems to permit a more accurate assessment.
This study also emphasizes the necessity of intraindividual comparisons and demonstrates that NIS protein expression does not reflect NIS mRNA expression. This difference indicates that posttranscriptional factors are likely to play an important role. Moreover, reduced NIS mRNA expression does not seem to be the decisive factor in the impairment of the iodine-concentrating ability of CTNs, but posttranslational factors such as the transport of the NIS protein to the plasma membrane are likely to be disturbed in CTNs. Furthermore, alterations in other proteins interacting with or regulating NIS are conceivable in CTNs.
